Dapagliflozin, sold under the brand names Farxiga (US) and Forxiga (EU) among others, is a medication used to treat type 2 diabetes. It is also used to treat adults with heart failure and chronic kidney disease. It reversibly inhibits sodium-glucose co-transporter 2 (SGLT-2) in the renal proximal convoluted tubule to reduce glucose reabsorption and increase urinary glucose excretion.

Common side effects include hypoglycaemia (low blood sugar), urinary tract infections, genital infections, and volume depletion (reduced amount of water in the body). Diabetic ketoacidosis is a common side effect in people with type 1 diabetes. Serious but rare side effects include Fournier gangrene.

It was developed by Bristol-Myers Squibb in partnership with AstraZeneca. It is on the World Health Organization's List of Essential Medicines. In 2023, it was the 92nd most commonly prescribed medication in the United States, with more than 7 million prescriptions. Dapagliflozin is available as a generic medication.

Dapagliflozin is used along with diet, exercise, and usually with other glucose-lowering medications, to improve glycaemic control in adults with type 2 diabetes. Dapagliflozin, in addition to other SGLT2 inhibitors, was shown to reduce the rate of decline in kidney function and kidney failure in non-diabetic and type 2 diabetic adults when added to the existing treatment regimen.

Guidelines including the European Society of Cardiology for Heart Failure and American Heart Association consider SGLT2 inhibitors such as dapagliflozin as standard therapy for people with heart failure with reduced ejection fraction, (LVEF < 40%). This is supported by 2 large randomized controlled trials and a 2023 systematic review and meta-analysis.

There is evidence from multiple studies that the addition of dapagliflozin and other medications from the SGLT2 inhibitor class to standard heart failure therapy can reduce the risk of worsening heart failure, hospitalisation for heart failure and cardiovascular death, regardless of the presence or absence of diabetes. This benefit has been mostly studied in patients with heart failure with reduced ejection fraction (LVEF <40%) but there are emerging studies showing benefit in patients with heart failure with mildly reduced or preserved ejection fraction (LVEF >40%) and there may also be some benefit for its use in acute heart failure as part of diuresis. SGLT-2 inhibitors reduce the risk of hospitalisation due to heart failure in people with or without atherosclerotic cardiovascular disease. Some meta-analyses and cohort studies suggest that dapagliflozin may provide advantages compared to other SGLT2 inhibitors like empagliflozin in specific heart failure hospitalisation, but the results can vary, and further comparative studies are required to establish consistent superiority.

In the European Union, dapagliflozin is indicated in adults:

In November 2021, the European Medicines Agency (EMA) stated that dapagliflozin should no longer be used to treat type 1 diabetes.